Phase 1a/1b study design of the novel STING agonist, immune-stimulating antibody-conjugate (ISAC) TAK-500, with or without pembrolizumab in patients with advanced solid tumors.

肿瘤微环境 癌症研究 医学 头颈部鳞状细胞癌 免疫检查点 免疫学 先天免疫系统 免疫疗法 彭布罗利珠单抗 免疫系统 癌症 内科学 头颈部癌
作者
Jennifer R. Diamond,Jason T. Henry,Gerald S. Falchook,Anthony J. Olszanski,Harshabad Singh,E. Jane Leonard,Richard C. Gregory,Vicky A. Appleman,John P. Gibbs,Carole Harbison,Jia Li,Jessica M. Sapiro,T Yoneyama,Alexander Parent,Vincent Chung
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:40 (16_suppl): TPS2690-TPS2690 被引量:8
标识
DOI:10.1200/jco.2022.40.16_suppl.tps2690
摘要

TPS2690 Background: Tumor resistance to immune checkpoint inhibitors (CPIs), including pembrolizumab, is common. Suggested mechanisms of resistance include reduced interferon (IFN) signaling, immune escape, and immunosuppressive tumor phenotypes. Innate immune cell stimulation in the tumor microenvironment may be a potential pathway to overcome this resistance. Stimulator of interferon genes (STING) is a cytosolic protein critical for initiation of type-1 IFN-dependent innate immunity. TAK-500 is a novel ISAC comprising a STING agonist (based on TAK-676, which is currently in phase 1 clinical trials [NCT04420884, NCT04879849]), an IgG1 anti-cysteine-cysteine chemokine receptor 2 (CCR2) antibody, and a self-immolating maleimide-containing protease-cleavable peptide linker. CCR2-expressing myeloid cells, including tumor associated macrophages (TAMs), promote immune evasion in part by reducing infiltration of CD8+ T cells into the tumor microenvironment. As such, TAK-500 has the potential to mitigate CPI resistance in solid tumors via targeted STING activation of tumor-infiltrating CCR2-expressing myeloid cells, thus leading to stimulation of innate and adaptive immunity within the tumor microenvironment through three potential mechanisms of action: activation of IFN signaling, reprogramming of CCR2-expressing myeloid cells to an inflammatory phenotype, and blockade of suppressive TAM recruitment. Methods: Adult patients with a diagnosis of locally advanced or metastatic gastroesophageal adenocarcinoma, pancreatic adenocarcinoma, hepatocellular carcinoma, non-squamous non-small cell lung cancer, squamous cell carcinoma of the head and neck, mesothelioma or triple-negative breast cancer are eligible. All patients must have progressive disease while on, or be intolerant to, all current standard therapies. Approximately 106 patients in total will be enrolled to the dose escalation and expansion cohorts. In the dose escalation phase, intravenous (IV) TAK-500 will be administered over the range 8–480 µg/kg on day 1 of every 21-day cycle (Q3W) to establish the pharmacologically active dose (PAD) range. An additional escalation cohort of patients will receive TAK-500 + IV pembrolizumab 200 mg Q3W, starting at a dose of TAK-500 that is 1–2 dose levels below the lowest PAD range established in the single agent cohort. Dose escalation in both cohorts will be guided by Bayesian Optimal Interval design. In the dose expansion phase, only the combination of TAK-500 + pembrolizumab will be evaluated. Primary objectives of this study are safety and tolerability; secondary objectives include determination of the PAD range, the recommended phase 2 dose, pharmacokinetics, pharmacodynamics, and antitumor activity of TAK-500 as a single agent and in combination with pembrolizumab. Clinical trial information: NCT05070247.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
nano完成签到 ,获得积分10
2秒前
慕容飞凤完成签到,获得积分10
2秒前
勤奋千风完成签到 ,获得积分10
5秒前
philophysics完成签到,获得积分10
8秒前
Jaja完成签到,获得积分10
10秒前
wushuimei完成签到 ,获得积分10
11秒前
tt完成签到 ,获得积分10
12秒前
18秒前
Tim完成签到 ,获得积分10
19秒前
Oct完成签到 ,获得积分10
26秒前
26秒前
皮皮球完成签到 ,获得积分10
27秒前
黄金天下完成签到,获得积分10
28秒前
北城完成签到 ,获得积分10
32秒前
llhh2024完成签到,获得积分10
34秒前
水盒子完成签到,获得积分10
36秒前
i2stay完成签到,获得积分10
36秒前
nt1119完成签到 ,获得积分10
37秒前
成就的绮烟完成签到 ,获得积分10
39秒前
月潮共生完成签到 ,获得积分10
41秒前
果果完成签到,获得积分10
49秒前
细心的代天完成签到 ,获得积分10
49秒前
lululululululu完成签到 ,获得积分10
50秒前
jxas完成签到,获得积分10
51秒前
洁净青筠发布了新的文献求助10
53秒前
Ethan完成签到 ,获得积分10
1分钟前
Fly完成签到,获得积分10
1分钟前
阿拉斯加剪短毛完成签到 ,获得积分10
1分钟前
精明秋完成签到,获得积分10
1分钟前
我不会乱起名字的完成签到,获得积分10
1分钟前
nianshu完成签到 ,获得积分10
1分钟前
LSi奇完成签到 ,获得积分10
1分钟前
Shinchan完成签到 ,获得积分10
1分钟前
星叶完成签到 ,获得积分10
1分钟前
昏睡的沛柔完成签到 ,获得积分10
1分钟前
顺利毕业完成签到 ,获得积分10
1分钟前
1分钟前
mm完成签到,获得积分10
1分钟前
满意白卉完成签到 ,获得积分10
1分钟前
高分求助中
좌파는 어떻게 좌파가 됐나:한국 급진노동운동의 형성과 궤적 2500
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Cognitive linguistics critical concepts in linguistics 800
Threaded Harmony: A Sustainable Approach to Fashion 799
Livre et militantisme : La Cité éditeur 1958-1967 500
氟盐冷却高温堆非能动余热排出性能及安全分析研究 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3052652
求助须知:如何正确求助?哪些是违规求助? 2709874
关于积分的说明 7418298
捐赠科研通 2354492
什么是DOI,文献DOI怎么找? 1246104
科研通“疑难数据库(出版商)”最低求助积分说明 605951
版权声明 595921